Literature DB >> 2971673

Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor.

J A Koedam1, J C Meijers, J J Sixma, B N Bouma.   

Abstract

Activated protein C (APC) acts as a potent anticoagulant enzyme by inactivating Factor V and Factor VIII. In this study, protein S was shown to increase the inactivation of purified Factor VIII by APC ninefold. The reaction rate was saturated with respect to the concentration of protein S when protein S was present in a 10-fold molar excess over APC. The heavy chain of Factor VIII was cleaved by APC and protein S did not alter the degradation pattern. Factor VIII circulates in a complex with the adhesive protein von Willebrand factor. When purified Factor VIII was recombined with von Willebrand factor, the inactivation of Factor VIII by APC proceeded at a 10-20-fold slower rate as compared with Factor VIII in the absence of von Willebrand factor. Protein S had no effect on the inactivation of the Factor VIII-von Willebrand factor complex by APC. After treatment of this complex with thrombin, however, the actions of APC and protein S towards Factor VIII were completely restored. In hemophilia A plasma, purified Factor VIII associated with endogenous von Willebrand factor, resulting in a complete protection against APC (4 nM). By mixing hemophilic plasma with plasma from a patient with severe von Willebrand's disease, we could vary the amount of von Willebrand factor. 1 U of von Willebrand factor was needed to provide protection of 1 U Factor VIII. Also in plasma from patients with the IIA-type variant of von Willebrand's disease, Factor VIII was protected. In von Willebrand's disease plasma, which was depleted of protein S, APC did not inactivate Factor VIII. These results indicate that protein S serves as a cofactor in the inactivation of Factor VIII and Factor VIIIa by APC and that von Willebrand factor can regulate the action of these two anticoagulant proteins.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2971673      PMCID: PMC442674          DOI: 10.1172/JCI113721

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  52 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Human factor VIII: purification from commercial factor VIII concentrate, characterization, identification and radiolabeling.

Authors:  R J Hamer; J A Koedam; N H Beeser-Visser; J J Sixma
Journal:  Biochim Biophys Acta       Date:  1986-10-17

3.  The regulation of natural anticoagulant pathways.

Authors:  C T Esmon
Journal:  Science       Date:  1987-03-13       Impact factor: 47.728

4.  Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity.

Authors:  D Eaton; H Rodriguez; G A Vehar
Journal:  Biochemistry       Date:  1986-01-28       Impact factor: 3.162

5.  Detection of the carrier state in hereditary coagulation disorders. I.

Authors:  J J Veltkamp; E F Drion; E A Loeliger
Journal:  Thromb Diath Haemorrh       Date:  1968-03-31

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  The effect of thrombin on the complex between factor VIII and von Willebrand factor.

Authors:  R J Hamer; J A Koedam; N H Beeser-Visser; J J Sixma
Journal:  Eur J Biochem       Date:  1987-09-01

8.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

9.  Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain.

Authors:  R J Hamer; J A Koedam; N H Beeser-Visser; R M Bertina; J A Van Mourik; J J Sixma
Journal:  Eur J Biochem       Date:  1987-07-01

10.  Immunologic studies of antihemophilic factor (AHF, factor VIII). IV. Radioimmunoassay of AHF antigen.

Authors:  L W Hoyer
Journal:  J Lab Clin Med       Date:  1972-12
View more
  28 in total

1.  Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III.

Authors:  S Lethagen; E Berntorp; I M Nilsson
Journal:  Ann Hematol       Date:  1992-12       Impact factor: 3.673

Review 2.  The interaction between complement component C4b-binding protein and the vitamin K-dependent protein S forms a link between blood coagulation and the complement system.

Authors:  M Hessing
Journal:  Biochem J       Date:  1991-08-01       Impact factor: 3.857

Review 3.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

4.  Characterization of mini-protein S, a recombinant variant of protein S that lacks the sex hormone binding globulin-like domain.

Authors:  M Van Wijnen; J G Stam; G T Chang; J C Meijers; P H Reitsma; R M Bertina; B N Bouma
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

5.  Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma.

Authors:  Coen Maas; Joost C M Meijers; J Arnoud Marquart; Kamran Bakhtiari; Cees Weeterings; Philip G de Groot; Rolf T Urbanus
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-03       Impact factor: 11.205

6.  Genetic determinants of variation in the plasma levels of the C4b-binding protein (C4BP) in Spanish families.

Authors:  Jorge Esparza-Gordillo; José Manuel Soria; Alfonso Buil; Joan Carles Souto; Laura Almasy; John Blangero; Jordi Fontcuberta; Santiago Rodríguez de Córdoba
Journal:  Immunogenetics       Date:  2003-02-22       Impact factor: 2.846

7.  C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein S-independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies.

Authors:  Alfonso Buil; David-Alexandre Trégouët; Juan Carlos Souto; Noémie Saut; Marine Germain; Maxime Rotival; Laurence Tiret; Françcois Cambien; Mark Lathrop; Tanja Zeller; Marie-Christine Alessi; Santiago Rodriguez de Cordoba; Thomas Münzel; Philipp Wild; Jordi Fontcuberta; France Gagnon; Joseph Emmerich; Laura Almasy; Stefan Blankenberg; José-Manuel Soria; Pierre-Emmanuel Morange
Journal:  Blood       Date:  2010-03-08       Impact factor: 22.113

8.  Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimeras.

Authors:  T C Nichols; C M Samama; D A Bellinger; J Roussi; R L Reddick; M Bonneau; M S Read; O Bailliart; G G Koch; M Vaiman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

Review 9.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009

10.  Evidence that a secondary binding and protecting site for factor VIII on von Willebrand factor is highly unlikely.

Authors:  S Layet; J P Girma; B Obert; E Peynaud-Debayle; N Bihoreau; D Meyer
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.